Who has the upper ground in a war between investors and short-sellers about whether a biotech's clinical trial for treating head and neck cancer can succeed?
News & Analysis: CEL-SCI
These stocks were huge winners last week. But can their momentum continue?
Our investing community's latest pick to avoid: Vical.
More on investing in "baby biotechs."
Finally, a phase 3 trial for cancer therapy Multikine.